Global Pruritus Therapeutics Market is expected to reach USD 16.38 Billion by 2025, according to a new study by Grand View Research, Inc. Growing worldwide prevalence of atopic dermatitis, allergic contact dermatitis and urticaria is expected to drive market growth during the forecast period. Introduction of new products based on scientific mechanistic understanding such as the identification of new T-cell subsets, particularly Th17, and Th22 and the patent expiration of PROTOPIC (tacrolimus) is expected to open up new avenues for manufacturers to capitalize on over the forecast period.
Corticosteroids were the leading product
segment in 2013 owing to high efficacy exhibited by this class of drugs in
treating pruritic conditions by reducing inflammation and itching. Topical
applications of corticosteroids have been found to be extremely effective in
the treatment and maintenance therapies pertaining to pruritus.
Browse Details of Report @ http://www.grandviewresearch.com/industry-analysis/pruritus-therapeutics-market
Further key
findings from the study suggest:
- Calcineurin inhibitor is identified as the most lucrative segment
of the market on account of high usage rate of these drugs in combination
therapy for the treatment of pruritus in patients suffering from chronic
pruritus and growing market penetration rates. Moreover, the introduction
of new products such as Pimecrolimus cream and Tacrolimus ointment is
expected to further drive this market.
- Anti-histamines owing to its growing use as a first line treatment
and presence of drugs in pipeline with expected commercialization is also
expected to grow at a healthy rate during the forecast period.
- North America led the overall market in terms of revenue in 2013
majorly on account of the presence of high prevalence of diseases
associated with pruritus, introduction of new products targeting the unmet
medical needs and growing patient awareness levels.
- The Asia Pacific pruritus therapeutics market is expected to grow
at a CAGR of over 5.0% during the forecast period. Presence of high unmet
healthcare needs and increasing prevalence of allergic contact dermatitis
and urticaria in this region are some factors attributing to its rapid
growth rate.
- Some key participants of the pruritus therapeutics market include
Sanofi, Pfizer, Tai Guk Pharmaceutical Company, Actavis, Trevi
Therapeutics, Cara Therapeutics, Ocera Therapeutics Inc. and NeRRe
Therapeutics.
- Manufacturers adhere to rigorous R&D in an attempt to develop
cost effective products and avoid barriers such as product recalls. In
addition, this strategy is implemented keeping the unmet needs in
consideration. For Instance, Creabilis has a molecule in the pipeline –
CT327, which caters to the unmet needs associated with pruritus in
patients suffering from psoriasis.
About Us:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment